Our Pipeline

Exxel Pharma’s pipeline counts two functionally distinct FAAH inhibitors, URB937 and the URB597-based ARN molecules. URB937 is peripherally restricted (i.e., is inactive in the brain and spinal cord), whereas the ARN molecules are global active FAAH inhibitors. The therapeutics were developed at the University of California, Irvine by our Chief Scientific Officer, Professor Daniele Piomelli, and are protected by multiple issued and pending patents. URB937 is positioned as a novel treatment for chronic cough. The URB597-based ARN molecules are being developed for treatment of PTSD and other diseases of the CNS.

Product Pipeline

  • URB937 for management of chronic cough
  • URB597 for PTSD and other diseases of the CNS


  • UC Irvine for preclinical development activities and new generation molecules.